Therapeutic advances in endocrinology and metabolism · 2026
Determination of the relationship between raftlin, oxidative stress levels, and vitamin D receptor gene polymorphism in diabetic patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guzelgul Figen, Bozkurt Nihan, Catak Merve, Sahin Kubra, Abdelmageed Marwa, Gezh Shahab Ahmed Salih, Savkin Sadegul
Аннотация
BACKGROUND: The pathogenesis of diabetes is affected by a complex interplay between numerous environmental and genetic factors. While single-nucleotide polymorphisms (SNPs) are not directly used as biomarkers of the disease, they can be considered an important guide for determining predisposition.
OBJECTIVE: To investigate the roles of raftlin, malondialdehyde (MDA), superoxide dismutase (SOD), and the vitamin D receptor (VDR) BsmI (rs1544410 A>G) polymorphism, in the clinical progression of type 2 diabetes mellitus (T2DM).
DESIGN: A retrospective observational case-control study.
METHODS: A total of 300 subjects were included in the study: 104 with T2DM, 85 with prediabetes, and 111 healthy controls. The VDR BsmI polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, while serum MDA, SOD, and raftlin were analyzed via the enzyme-linked immunosorbent assay (ELISA) method.
RESULTS: No statistically significant differences were observed in the allelic and genotype frequencies of the VDR gene BsmI polymorphism between T2DM prediabetes patients and controls (p = 0.97, p = 0.58, respectively). MDA levels were higher, while raftlin levels were lower in patients with T2DM and prediabetes compared to controls (p < 0.05). Within the T2DM cohort, HbA1c (p = 0.014), MDA (p = 0.001), and raftlin (p < 0.001) differed significantly between the BB and bb genotypes, with a positive correlation between the bb genotype and HbA1c (p = 0.008, r = 0.287). Receiver operating characteristic (ROC) analysis revealed raftlin's diagnostic potential among T2DM patients with the BB and bb genotypes, with an area under the curve (AUC) of 0.839, a specificity of 69.2%, and a sensitivity of 81.5%.
CONCLUSION: To the best of our knowledge, this is the first study to demonstrate that raftlin exhibits significant diagnostic efficacy in individuals with the bb genotype within a clinical T2DM cohort.
OBJECTIVE: To investigate the roles of raftlin, malondialdehyde (MDA), superoxide dismutase (SOD), and the vitamin D receptor (VDR) BsmI (rs1544410 A>G) polymorphism, in the clinical progression of type 2 diabetes mellitus (T2DM).
DESIGN: A retrospective observational case-control study.
METHODS: A total of 300 subjects were included in the study: 104 with T2DM, 85 with prediabetes, and 111 healthy controls. The VDR BsmI polymorphism was genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, while serum MDA, SOD, and raftlin were analyzed via the enzyme-linked immunosorbent assay (ELISA) method.
RESULTS: No statistically significant differences were observed in the allelic and genotype frequencies of the VDR gene BsmI polymorphism between T2DM prediabetes patients and controls (p = 0.97, p = 0.58, respectively). MDA levels were higher, while raftlin levels were lower in patients with T2DM and prediabetes compared to controls (p < 0.05). Within the T2DM cohort, HbA1c (p = 0.014), MDA (p = 0.001), and raftlin (p < 0.001) differed significantly between the BB and bb genotypes, with a positive correlation between the bb genotype and HbA1c (p = 0.008, r = 0.287). Receiver operating characteristic (ROC) analysis revealed raftlin's diagnostic potential among T2DM patients with the BB and bb genotypes, with an area under the curve (AUC) of 0.839, a specificity of 69.2%, and a sensitivity of 81.5%.
CONCLUSION: To the best of our knowledge, this is the first study to demonstrate that raftlin exhibits significant diagnostic efficacy in individuals with the bb genotype within a clinical T2DM cohort.